Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. TherapeuticsMD's annualizedGross Profit for the quarter that ended in Mar. 2024 was $1.25 Mil.
TherapeuticsMD's average Total Assets over the quarter that ended in Mar. 2024 was $42.70 Mil. Therefore, TherapeuticsMD's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2024 was 2.93%.
TherapeuticsMD Gross-Profit-to-Asset % Historical Data
The historical data trend for TherapeuticsMD's Gross-Profit-to-Asset % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of TherapeuticsMD's Gross-Profit-to-Asset %
For the Drug Manufacturers - Specialty & Generic subindustry, TherapeuticsMD's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TherapeuticsMD's Gross-Profit-to-Asset % Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, TherapeuticsMD's Gross-Profit-to-Asset % distribution charts can be found below:
* The bar in red indicates where TherapeuticsMD's Gross-Profit-to-Asset % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Gross Profit data used here is four times the quarterly (Mar. 2024) data.
Gross-Profit-to-Asset % is displayed in the 30-year financial page.
TherapeuticsMD Gross-Profit-to-Asset % Related Terms
Thank you for viewing the detailed overview of TherapeuticsMD's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.
TherapeuticsMD (TherapeuticsMD) Business Description
TherapeuticsMD Inc is a major drug manufacturing with a focus on creating and commercializing products targeted exclusively for women. The company intends to commercialize advanced hormone therapy pharmaceutical products. TherapeuticsMD's drug candidates that have completed clinical trials are designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis, and discomfort. The company relies on third parties for the production of clinical and commercial quantities of its drug candidates.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
TXMD has been successfully added to your 